Biohaven Ltd. Research and Development Expense
Biohaven Ltd. (BHVN) reported Research and Development Expense of $100.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-10
- Biohaven Ltd. research and development expense for the quarter ending 2026-06-30 was $100.81M, a 45.32% decline year-over-year.
- Biohaven Ltd. research and development expense for the quarter ending 2026-03-31 was $103.83M, a 44.65% decline year-over-year.
- Biohaven Ltd. research and development expense for the quarter ending 2025-12-31 was $121.94M, a 27.19% decline year-over-year.
- Biohaven Ltd. research and development expense for the quarter ending 2025-09-30 was $141.17M, a 10.43% decline year-over-year.
- Biohaven Ltd. research and development expense for fiscal 2025 was $635.07M, a 20.21% decline from fiscal 2024.
- Biohaven Ltd. research and development expense for fiscal 2024 was $795.87M, a 113.21% increase from fiscal 2023.
- Biohaven Ltd. research and development expense for fiscal 2023 was $373.28M, a 14.60% decline from fiscal 2022.
- Biohaven Ltd. research and development expense for fiscal 2022 was $437.07M, a 140.83% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $100.81M 10-Q · filed 2026-08-10 | $204.64M 10-Q · filed 2026-08-10 | $326.59M derived: sum of 3 quarters · filed 2026-08-10 | $467.75M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $103.83M 10-Q · filed 2026-05-04 | $225.77M derived: sum of 2 quarters · filed 2026-05-04 | $366.94M derived: sum of 3 quarters · filed 2026-05-04 | $551.31M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $121.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $263.11M derived: sum of 2 quarters · filed 2026-03-02 | $447.48M derived: sum of 3 quarters · filed 2026-08-10 | $635.07M 10-K · filed 2026-03-02 |
| 2025-09-30 | $141.17M 10-Q · filed 2025-11-10 | $325.54M derived: sum of 2 quarters · filed 2026-08-10 | $513.12M 10-Q · filed 2025-11-10 | $680.59M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $184.37M 10-Q · filed 2026-08-10 | $371.95M 10-Q · filed 2026-08-10 | $539.42M derived: sum of 3 quarters · filed 2026-08-10 | $697.03M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $187.58M 10-Q · filed 2026-05-04 | $355.06M derived: sum of 2 quarters · filed 2026-05-04 | $512.66M derived: sum of 3 quarters · filed 2026-05-04 | $827.48M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $167.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $325.08M derived: sum of 2 quarters · filed 2026-03-02 | $639.90M derived: sum of 3 quarters · filed 2026-03-02 | $795.87M 10-K · filed 2026-03-02 |
| 2024-09-30 | $157.61M 10-Q · filed 2025-11-10 | $472.43M derived: sum of 2 quarters · filed 2025-11-10 | $628.40M 10-Q · filed 2025-11-10 | $763.21M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $314.82M 10-Q · filed 2025-08-11 | $470.79M 10-Q · filed 2025-08-11 | $605.60M derived: sum of 3 quarters · filed 2026-03-02 | $701.12M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $155.97M 10-Q · filed 2025-05-12 | $290.79M derived: sum of 2 quarters · filed 2026-03-02 | $386.30M derived: sum of 3 quarters · filed 2026-03-02 | $465.79M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $134.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $230.33M derived: sum of 2 quarters · filed 2026-03-02 | $309.82M derived: sum of 3 quarters · filed 2026-03-02 | $373.28M 10-K · filed 2026-03-02 |
| 2023-09-30 | $95.52M 10-Q · filed 2024-11-12 | $175.01M derived: sum of 2 quarters · filed 2024-11-12 | $238.47M 10-Q · filed 2024-11-12 | $375.51M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $79.49M 10-Q · filed 2024-08-09 | $142.95M 10-Q · filed 2024-08-09 | $280.00M derived: sum of 3 quarters · filed 2025-03-03 | $332.84M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $63.46M 10-Q · filed 2024-05-09 | $200.50M derived: sum of 2 quarters · filed 2025-03-03 | $253.35M derived: sum of 3 quarters · filed 2025-03-03 | $430.44M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $137.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $189.89M derived: sum of 2 quarters · filed 2025-03-03 | $366.98M derived: sum of 3 quarters · filed 2025-03-03 | $437.07M 10-K · filed 2025-03-03 |
| 2022-09-30 | $52.84M 10-Q · filed 2023-11-14 | $229.93M derived: sum of 2 quarters · filed 2023-11-14 | $300.03M 10-Q · filed 2023-11-14 | $341.85M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $177.09M 10-Q · filed 2023-07-31 | $247.18M 10-Q · filed 2023-07-31 | $289.00M derived: sum of 3 quarters · filed 2024-02-29 | $335.97M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $70.10M 10-Q · filed 2023-05-12 | $111.91M derived: sum of 2 quarters · filed 2024-02-29 | $158.89M derived: sum of 3 quarters · filed 2024-02-29 | |
| 2021-12-31 | $41.82M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $88.79M derived: sum of 2 quarters · filed 2024-02-29 | $181.49M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $46.97M 10-Q · filed 2022-11-09 | $139.67M 10-Q · filed 2022-11-09 | ||
| 2020-12-31 | $98.46M 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |